Current Landscape of Hydroxamic Acid Derivatives With Antileukemia Activity

IF 3.6 3区医学 Q2 CHEMISTRY, MEDICINAL

Archiv der Pharmazie Pub Date : 2025-07-29 DOI:10.1002/ardp.70056

Yao Qu, Chang-Jin Yuan

{"title":"Current Landscape of Hydroxamic Acid Derivatives With Antileukemia Activity","authors":"Yao Qu, Chang-Jin Yuan","doi":"10.1002/ardp.70056","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Leukemia, as the second most prevalent hematological malignancy, could disrupt the production of healthy blood cells in the bone marrow, leading to anemia, neutropenia, and thrombocytopenia, and constitutes a significant global health burden. Chemotherapy remains a cornerstone of leukemia treatment, but drug resistance and severe adverse effects are the main culprits for its failure in treating leukemia, thereby creating an urgent imperative to develop innovative anti-leukemia agents. Hydroxamic acid derivatives, recognized as prominent histone deacetylase (HDAC) inhibitors, represent a promising class of agents in leukemia therapy, leveraging epigenetic modulation, multi-target activity, and synergistic potential to address unmet drug resistance and toxicity needs. This review summarizes the latest advancements in hydroxamic acid derivatives, including hydroxamic acid-azole hybrids, hydroxamic acid-indole hybrids, hydroxamic acid-pyridine/quinoline hybrids, and hydroxamic acid-(fused) pyrimidine hybrids, with therapeutic potential against leukemia, covering articles published from 2020 to the present. The structure–activity relationships and the mechanisms of action are also discussed to guide the rational design and development of more effective and less toxic therapeutic candidates.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 7","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70056","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Leukemia, as the second most prevalent hematological malignancy, could disrupt the production of healthy blood cells in the bone marrow, leading to anemia, neutropenia, and thrombocytopenia, and constitutes a significant global health burden. Chemotherapy remains a cornerstone of leukemia treatment, but drug resistance and severe adverse effects are the main culprits for its failure in treating leukemia, thereby creating an urgent imperative to develop innovative anti-leukemia agents. Hydroxamic acid derivatives, recognized as prominent histone deacetylase (HDAC) inhibitors, represent a promising class of agents in leukemia therapy, leveraging epigenetic modulation, multi-target activity, and synergistic potential to address unmet drug resistance and toxicity needs. This review summarizes the latest advancements in hydroxamic acid derivatives, including hydroxamic acid-azole hybrids, hydroxamic acid-indole hybrids, hydroxamic acid-pyridine/quinoline hybrids, and hydroxamic acid-(fused) pyrimidine hybrids, with therapeutic potential against leukemia, covering articles published from 2020 to the present. The structure–activity relationships and the mechanisms of action are also discussed to guide the rational design and development of more effective and less toxic therapeutic candidates.

Abstract Image

查看原文本刊更多论文

具有抗白血病活性的羟肟酸衍生物的研究现状

白血病是第二大最常见的血液恶性肿瘤，可破坏骨髓中健康血细胞的产生，导致贫血、中性粒细胞减少症和血小板减少症，并构成重大的全球健康负担。化疗仍然是白血病治疗的基石，但耐药性和严重的不良反应是其治疗白血病失败的主要原因，因此迫切需要开发创新的抗白血病药物。羟肟酸衍生物，被认为是重要的组蛋白去乙酰化酶（HDAC）抑制剂，代表了白血病治疗中有前途的一类药物，利用表观遗传调节、多靶点活性和协同潜力来解决未满足的耐药性和毒性需求。本文综述了从2020年至今发表的具有治疗白血病潜力的羟肟酸衍生物的最新进展，包括羟肟酸-唑类化合物、羟肟酸-吲哚类化合物、羟肟酸-吡啶/喹啉类化合物以及羟肟酸-（融合）嘧啶类化合物。本文还讨论了它们的构效关系和作用机制，以指导合理设计和开发更有效、毒性更小的候选治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archiv der Pharmazie 医学-化学综合

CiteScore

7.90

自引率

5.90%

发文量

176

审稿时长

3.0 months

期刊介绍： Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.